Skip to main content

Table 3 Analytical sensitivity of CRISPR-CPPC assay in detecting EGFR T790M mutation

From: Application of CRISPR/Cas9-based mutant enrichment technique to improve the clinical sensitivity of plasma EGFR testing in patients with non-small cell lung cancer

Reference Materials (T790M)

Expected allele frequency (%)*

Expected copies of mutant DNA per sample*

Expected copies of wild-type DNA per sample*

CRISPR-CPPC assay

Detection positive (≥ 6 events/assay)

Observed Mutant allele frequency (%)

Copies of mutant DNA per sample

Copies of wild-type DNA per sample

5% Multiplex I cfDNA Reference Standard (HD777), 20 ng/µL

4.9

109

2120

8.8

231

2409

1% Multiplex I cfDNA Reference Standard (HD778), 20 ng/µL

1.1

24

2256

1.7

60

3376

0.1% Multiplex I cfDNA Reference Standard (HD779), 20 ng/µL

0.1

3

2228

0.5

19

3842

  1. cfDNA, cell-free DNA; CRISPR-CPPC, CRISPR system combined with post-PCR cfDNA; ddPCR, droplet digital PCR
  2. * Expected allele frequency and copy number of wild-type and mutant DNA measured using ddPCR were provided by the manufacturer